TY - JOUR
T1 - PAK proteins and YAP-1 signalling downstream of integrin beta-1 in myofibroblasts promote liver fibrosis
AU - Martin, Katherine
AU - Pritchett, James
AU - Llewellyn, Jessica
AU - Mullan, Aoibheann F.
AU - Athwal, Varinder S.
AU - Dobie, Ross
AU - Harvey, Emma
AU - Zeef, Leo
AU - Farrow, Stuart
AU - Streuli, Charles
AU - Henderson, Neil C.
AU - Friedman, Scott L.
AU - Hanley, Neil A.
AU - Hanley, Karen Piper
N1 - Funding Information:
Medical Research Council (MRC; K.P.H., MR/J003352/1)
Publisher Copyright:
© The Author(s) 2016.
PY - 2016/8/18
Y1 - 2016/8/18
N2 - Fibrosis due to extracellular matrix (ECM) secretion from myofibroblasts complicates many chronic liver diseases causing scarring and organ failure. Integrin-dependent interaction with scar ECM promotes pro-fibrotic features. However, the pathological intracellular mechanism in liver myofibroblasts is not completely understood, and further insight could enable therapeutic efforts to reverse fibrosis. Here, we show that integrin beta-1, capable of binding integrin alpha-11, regulates the pro-fibrotic phenotype of myofibroblasts. Integrin beta-1 expression is upregulated in pro-fibrotic myofibroblasts in vivo and is required in vitro for production of fibrotic ECM components, myofibroblast proliferation, migration and contraction. Serine/threonine-protein kinase proteins, also known as P21-Activated kinase (PAK), and the mechanosensitive factor, Yes-Associated protein 1 (YAP-1) are core mediators of pro-fibrotic integrin beta-1 signalling, with YAP-1 capable of perpetuating integrin beta-1 expression. Pharmacological inhibition of either pathway in vivo attenuates liver fibrosis. PAK protein inhibition, in particular, markedly inactivates the pro-fibrotic myofibroblast phenotype, limits scarring from different hepatic insults and represents a new tractable therapeutic target for treating liver fibrosis.
AB - Fibrosis due to extracellular matrix (ECM) secretion from myofibroblasts complicates many chronic liver diseases causing scarring and organ failure. Integrin-dependent interaction with scar ECM promotes pro-fibrotic features. However, the pathological intracellular mechanism in liver myofibroblasts is not completely understood, and further insight could enable therapeutic efforts to reverse fibrosis. Here, we show that integrin beta-1, capable of binding integrin alpha-11, regulates the pro-fibrotic phenotype of myofibroblasts. Integrin beta-1 expression is upregulated in pro-fibrotic myofibroblasts in vivo and is required in vitro for production of fibrotic ECM components, myofibroblast proliferation, migration and contraction. Serine/threonine-protein kinase proteins, also known as P21-Activated kinase (PAK), and the mechanosensitive factor, Yes-Associated protein 1 (YAP-1) are core mediators of pro-fibrotic integrin beta-1 signalling, with YAP-1 capable of perpetuating integrin beta-1 expression. Pharmacological inhibition of either pathway in vivo attenuates liver fibrosis. PAK protein inhibition, in particular, markedly inactivates the pro-fibrotic myofibroblast phenotype, limits scarring from different hepatic insults and represents a new tractable therapeutic target for treating liver fibrosis.
UR - http://www.scopus.com/inward/record.url?scp=84983326095&partnerID=8YFLogxK
U2 - 10.1038/ncomms12502
DO - 10.1038/ncomms12502
M3 - Article
C2 - 27535340
AN - SCOPUS:84983326095
SN - 2041-1723
VL - 7
JO - Nature Communications
JF - Nature Communications
M1 - 12502
ER -